Comprehensive Geriatric Assessment in Men Aged 70 Years or Older with Localised Prostate Cancer Undergoing Radical Radiotherapy

G.E.C. Osborne(University Hospitals Sussex NHS Foundation Trust), Alistair Ring(National Health Service), E. Peasgood(University Hospitals Sussex NHS Foundation Trust), Angus Robinson(Royal Sussex County Hospital), Christopher I. Jones(Florence Nightingale Foundation), Sharon A. Appleyard(Commonwealth Scientific and Industrial Research Organisation), Duncan C. Gilbert(Royal Sussex County Hospital), Ashok Nikapota(University Hospitals Sussex NHS Foundation Trust), M.J. Villanueva(University Hospitals Sussex NHS Foundation Trust), C. Lorimer(University Hospitals Sussex NHS Foundation Trust)
Clinical Oncology
June 4, 2017
10.1016/j.clon.2017.05.003
Cited by 27

Related Papers

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Mechanisms of tamoxifen resistance
|Endocrine Related Cancer|2004|652
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
|The Lancet Oncology|2019|649
Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer
|JAMA Oncology|2019|425